Literature DB >> 30229852

Clinical treatment efficiency of mechanical thrombectomy combined with rhPro-UK thrombolysis for acute moderate/severe cerebral infarction.

Q-S Zhao1, W Li, D Li, T Liu, J-H Wang, Y Gao, L Yi, R-K Zhao.   

Abstract

OBJECTIVE: This study aims to compare clinical efficiency of mechanical thrombectomy combined with rhPro-UK thrombolysis on moderate or severe acute brain infarction. PATIENTS AND METHODS: A total of 90 acute cerebral infarction patients due to artery stenosis or blockade from May 2016 to May 2017 were recruited and randomly assigned into thrombolysis group (N = 30), mechanical thrombectomy (N = 30), and combined treatment group (N = 30). Clinical information was collected. Thrombolysis group received rhPro-UK, mechanical thrombectomy group received Solitaire scaffold, and combined group received rhPro-UK after Solitaire scaffold. Barthel scale and NIHSS scale were used to evaluate the quality of life and mental deficit of patients. Modified thrombolysis in cerebral infarction (mTICI) was compared among three groups, along with the observation of hemorrhage, neurological recovery within 90 days, and adverse effects.
RESULTS: No significant difference was found in NIHSS within 24 h of treatment among three groups (p > 0.05), but the decreasing levels were shown at 24 h, 7 days, and 90 days comparing to those before treatment (p < 0.05). In combined treatment group, lower NIHSS at 7 d and 90 d were detected comparing to other two groups (p < 0.05). Recanalization rates were 53.33% and 60.00% in thrombolysis and mechanical groups (p > 0.05), respectively, which were significantly lower than that in combined group (83.33%) (p < 0.05). Curative rate in combined group was 70%, significantly higher than thrombolysis (46.67%) and mechanical group (53.33%) (p < 0.05). No statistical difference of curative rate was observed between thrombolysis and mechanical groups (p > 0.05). Moreover, neither significant difference of coagulation function nor platelet count was found among three groups (p > 0.05).
CONCLUSIONS: Mechanical thrombectomy combined with thrombolysis presented favorable efficiency in the treatment of moderate to severe acute cerebral infarction than single treatment, among which the occurrence of adverse effects were similar.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30229852     DOI: 10.26355/eurrev_201809_15842

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Effect of intravenous thrombolysis combined with mechanical thrombectomy on neurological function and short-term prognosis of patients with acute cerebral infarction.

Authors:  Yongchang Liu; Zhen Hong; Yan Li; Shaoquan Li; Qingran Liu; Songwang Xie; Junyong Wang; Jian Wang; Mingming Zheng
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

2.  Comparison of Efficacy and Safety of Recombinant Human Prourokinase and Alteplase in the Treatment of STEMI and Analysis of Influencing Factors of Efficacy.

Authors:  Yizhou Liu; Yulin Yang; Ying Li; Xiaoqing Peng
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-06       Impact factor: 2.629

3.  Intravenous Thrombolysis Combined with Arterial Thrombolysis (Bridging Therapy) Effectively Improves Vascular Recanalization Rate in Patients with Cerebral Infarction.

Authors:  Junting Huo; Wei Li; Yu Liu
Journal:  J Immunol Res       Date:  2022-07-26       Impact factor: 4.493

4.  Comparative study on treatment of acute cerebral infarction between mechanical thrombectomy by micro catheter and thrombectomy by Solitaire AB stent.

Authors:  Xiaoli Dong; Guodong Xu; Yaxue Song; Liang Ma; Tiantian Huo; Nan Yin; Nan Meng
Journal:  Medicine (Baltimore)       Date:  2022-04-08       Impact factor: 1.817

5.  Mechanical thrombectomy for a 12-year-old boy with acute ischemic stroke: A case report.

Authors:  Yuchai Huang; Zhen Wang; Changluo Li; Ning Ding
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.